Gastric cancer is the third leading cause of death from cancer worldwide. Systemic chemotherapy remains the mainstay therapeutic option for this poor prognosis cancer. Trastuzumab, the epidermal growth factor receptor 2 (ERBB2 or HER2)-antibody, is the only biological agent approved for the molecularly selected population of HER2-positive gastric cancer patients. Over the last decade, several groups have been working for deepening into the molecular characterization of gastric cancer, shedding some light into the heterogeneity of this tumour. The published data have broadened the landscape towards a future molecular classification into several subtypes of gastric cancer, enabling a better selection of the optimal therapeutic strategy. The fibroblast growth factor receptor (FGFR) pathway plays a key role in gastric cancer pathogenesis, with 1.2%-9% of gastric cancer patients harbouring FGFR2 amplifications. Several selective FGFR inhibitors have been developed in the last years, with promising efficacy signals. However, there is still scarce evidence of the most reliant molecular determinants of response to these targeted agents. Homogeneous high-level clonal FGFR2-amplification, high FGFR2 mRNA or protein levels, specific FGFR2 C3 isoform expression, FGF ligand co-overexpression or detection of FGFR2 copy number in plasma circulating tumour DNA, are considered some of the potential predictive biomarkers to the FGFR inhibition. The successful development of highly specific FGFR inhibitors will rely on our capacity of establishing new personalized strategies, based on a deeper knowledge of the key alterations that drive oncogenesis in gastric cancer. Further efforts seem mandatory in order to implement accurate predictive biomarkers in the next stages of the FGFR inhibitors development.
Introduction
Gastric cancer (GC) is the fifth most common cancer worldwide, and the third leading cause of death from cancer, with nearly 723 073 deaths per year [1] . GC incidence notably varies by geographic region, with more than 70% of GC developed in lowincome countries, half of them detected in Eastern Asia.
Nearly two-thirds of newly diagnosed GC present with locally advanced or metastatic disease at diagnosis, therefore GC presents a significant dismal prognosis. Since 1997, systemic chemotherapy has positioned as the mainstay treatment option for these patients, yet the number of patients who benefit from treatment is still limited [2] . Over the last 20 years, efforts have been made in order to improve the results of initial chemotherapeutic regimens, using combinations of platinum salts and fluoropyrimidines as the more frequent backbone strategy with or without a third drug [3] . Nevertheless, there is still no international consensus regarding the optimal first-line combination [4] , with most of the regimens leading to a plateau in median overall survival (mOS) of 8-11.2 months [5] [6] [7] [8] .
In 2010, trastuzumab, the epidermal growth factor receptor 2 (ERBB2 or HER2)-antibody, opened the door towards a new era of incorporating targeted agents as part of the armamentarium for treating GC. The ToGA trial [9] showed a significantly benefit in mOS in the subset of HER2-positive patients treated within the cisplatinum-fluoropyrimidine-trastuzumab arm. Despite these promising results, trastuzumab remains the only biological agent approved for a molecularly selected population of GC patients.
During the last decade, several groups have tried to deepen into the molecular biology of the disease, aiming to develop a classification of molecularly differentiated subtypes of GC [10] [11] [12] [13] [14] . These classifications have shed more light on other potential oncogenic alterations that may drive tumourogenesis in GC, such as the fibroblast growth factor receptor 2 (FGFR2) aberrations. Certainly, further efforts are mandatory in order to define an optimal molecular classification of GC, allowing a progressive implementation of it in the design of molecularly guided clinical trials.
It is clear that there is a high unmet medical need in GC. Within this context where new treatments with an acceptable toxicity profile are urgently required, the FGFR/FGF pathway arises as a promising target to focus on in GC patients. Here we present an overview of the FGFR/FGF axis and the rationale for developing selective pan-FGFR inhibitors (FGFRinh) in GC, depicting the current status of different FGFRinh under development in GC and highlighting the challenges in finding accurate predictive biomarkers in this setting.
The FGFR/FGF pathway in gastric cancer
The FGFR/FGF cascade is a complex intracellular pathway that controls cellular proliferation and tumour growth, angiogenesis and dissemination. Four different membrane tyrosine kinase receptors are activated upon binding of one of the 23 different existing ligands, leading to the transphosphorylation of the new dimer. Subsequently, key adaptor proteins lead to downstream activation of the mitogen-activated protein kinase and the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathways [15] .
Deregulated FGFR/FGF pathway plays a critical role in several tumour types. To date, a variety of genetic aberrations of the FGFR and ligands have been described, which distribute unevenly across different solid malignancies [16] . Noteworthy, increased FGFR signalling may result from different types of genetic alterations: receptor gene translocations or activating point mutations that result into a constitutively activated ligand-independent kinase; gene amplifications which turn on to supraphysiological overexpression, either of the ligand or the receptor; altered splicing mechanisms leading to a paracrine or altered ligand expression [17] .
In 1990, FGFR2 amplification was described for the first time, after detecting an amplified DNA sequence from a KATO-III signet ring GC cell line [18] . Recently, the comprehensive analysis of several series has been able to identify patients harbouring this FGFR2 amplification in a proportion ranging from 9% (Western primary GC samples) [14] to 1.2%-4.9% (Asian primary GC samples) [13] . The oncogenic role of the FGFR2 kinase has been demonstrated by the selective growth inhibition of FGFR2-amplified (FGFR2amp) cancer cell lines by using shRNA or small-potent molecule inhibitors [19] , translated into decreased survival and tumour regression in in vivo models [20] . Furthermore, FGFR2 activating point mutations detected in GC samples support its important role in GC tumourogenesis [21] . FGFR2 gene amplification has been described as an independent poor prognostic factor in GC patients, associated with higher pT and pN, lymphovascular invasion and distant metastasis [22] [23] [24] .
Interestingly, genomic aberrations in HER2 (17%), MET (6%) and FGFR2 (9%) genes account among the most frequent oncogenic disorders described in GC patients [14] . However, these driver alterations seem to occur in largely distinct subgroups of GC, with very slight overlap between them [10, 11, 25] . Figure 1 depicts one of the most widely accepted molecular classifications of GC carried out by The Cancer Genome Atlas Research Network, positioning the subset of FGFR2amp GC patients within the chromosomal instability (CIN) subgroup.
As increasing data suggest that up-regulation of FGFR2 signalling is a key event in a subtype of GC, several FGFRinh have been developed with special focus on this subset of GC patients.
Selective pan-FGFR inhibitors under investigation in gastric cancer
FGFR2 amplifications have attracted significant attention as an emerging druggable candidate alteration for the development of directed novel anticancer agents. First generation multi-tyrosine kinase inhibitors have demonstrated antitumour activity against FGFRaberrant tumours [26] . However, due to their multi-targeting inhibition that translated into increased toxicity and the lack of a clear marker for predicting response, their further development has been limited [27, 28] . Over the last 5 years, the development of a second generation, highly selective pan-FGFR inhibitors has focused the interest, and several phase 1 trials have been enrolling FGFRaberrant tumours: AZD4547 (NCT00979134) [29] [30] [31] [32] , BGJ398 (NCT01004224) [33] , BAY1163877 (NCT01976741) [34] , Debio1347 (NCT01948297) [35] , LY28774455 (NCT01212107) [36] , JNJ-42756493 (NCT01703481) [37, 38] , PRN1371 (NCT02608125) [39] , TAS120 (NCT02052778) [40] and GSK3052230/FP-1039 (NCT01868022) [41] . However, as shown in Table 1 , only AZD4547 has demonstrated encouraging signs of efficacy among FGFR2amp GC patients so far.
AZD4547 is a small orally bioavailable selective inhibitor of the FGFR family. AZD4547 potently inhibits the tyrosine kinase activity of FGFR1, 2 and 3 (IC 50 <5 nM) [42] . In vitro studies have demonstrated that AZD4547 is able to suppress tumour growth through restraining cell proliferation, inhibiting invasion and migration and inducing apoptosis in FGFR-deregulated cell lines, with lack of antiproliferative effects in non-FGFR-aberrant cells. Furthermore, AZD4547 has efficiently shown tumour control in vivo in animal models, particularly in FGFR1 amplified (FGFR1amp) squamous non-small cell lung cancer (sqNSCLC) patient-derived xenografts (PDXs) [43, 44] and in FGFR2amp GC PDXs. In fact, compared with monotherapy, the combination with certain chemotherapeutic drugs such as paclitaxel, has demonstrated enhanced in vivo antitumour efficacy in GC models [20] . This preclinical data provided a strong rationale for considering further investigation with AZD4547 as a therapeutic option for FGFR2amp tumours.
A 3-part phase 1 study of AZD4547 in patients with advanced solid tumours was initiated (NCT00979134), aiming to: determine the maximum tolerated dose and a recommended phase 2 dose (RP2D) (part A), to evaluate the safety profile and pharmacokinetics (parts A and B) and to specifically assess efficacy in FGFR-aberrant patients (part C1) [29] . FGFR gene amplification status for enrolment in part C1 was assessed by fluorescent in situ hybridization (FISH) in fresh or archival tumour samples. The RP2D was established as 80 mg bi-daily (b.i.d.) in a continuous dosing regimen, with dose-limiting toxicities including stomatitis and mucositis, liver function tests deranged, hyperphosphatemia and renal failure. Five patients benefitted from AZD4547 in part C1, with four patients achieving stabilizations for !24 weeks (one breast cancer and one sqNSCLC, two bladder carcinomas [45] ). Of note, a partial response was reported in an FGFR1amp sqNSCLC. Detailed biomarker analysis using protein FGFR expression by immunohistochemistry (IHC), gene expression by Nanostring and targeted next generation sequencing (NGS), revealed that 7 out of 21 patients included in part C1 had high FGFR1amp (ratio FGFR: centromeric probe !3), and 3 of these were among the ones that presented long stabilizations or tumour reduction. Interestingly, NGS from the responding sqNSCLC patient confirmed high copy number FGFR1 amplification, together with amplification of 11q13 genes FGF3/4/19. A breast cancer patient that achieved durable stabilization with shrinkage of 25% in target lesions, presented high FGFR1 amplification and high FGFR1 protein expression [30] . In light of these promising results, Part C2 and C3 started enrolling FGFR1amp sqNSCLC [31] and FGFR2amp GC patients, respectively [32] .
A total of 238 advanced GC/GOJ patients were prospectively pre-screened by FISH in part C3; 38 patients (16%) met the prespecified FGFR2 threshold for amplification (FGFR: centromeric ratio !2), with only 13 patients being finally enrolled into this cohort. Six patients had high FGFR2 amplification (ratio !2.8), 3 had low amplification (ratio >2 to 2.8) and 4 presented a cluster type (>10% cells with clusters of FGFR amplification). Despite observing an encouraging partial response (cluster type patient) and four stabilizations (one cluster type and three highly amplified patients), the study did not meet the pre-specified overall response endpoint, and the GC expansion was discontinued [32] .
Early encouraging signs seen in this phase 1 study provided the evidence that AZD4547 had antitumour activity and caused pharmacologic FGFR inhibition at this dose, as increases in plasmatic phosphate levels were seen, which led to its further development in a phase 2 study. Of note, this phase 2 study was initiated before completing the enrolment and data analysis of the phase 1. The SHINE study (NCT01457846) aimed to assess further safety and efficacy of AZD4547 in FGFR2amp or polysomic GC after first line platinum-based failure [46] . Primary endpoint was progression-free survival (PFS), with FGFR2 status determined by central FISH. Patients were defined as FGFR2 polysomic (FISH 4/5), low (FISH 6, ratio >2) or high (FISH 6, ratio !5) amplified. Patients were assigned to polysomic or FGFR2amp arms and randomized to i.v. paclitaxel or oral AZD4547 80 mg b.i.d. intermittent schedule (2 weeks on/1 week off). 960 GC patients were enrolled into the study, with only 71 patients screened positive for FGFR2. Of these 71 FGFR2 patients, 41 patients were randomized in the AZD4547 arm (9 low and 9 high FGFR2amp) and 30 patients (10 low and 5 high FGFR2amp) in the chemotherapy arm. Thirty-five polysomic patients were enrolled, considering that they were less likely to display true oncogene addiction. Disappointingly, median PFS was 1.5 months for AZD4547 arm versus 2.3 months for paclitaxel arm. However, it has to be considered that these results included only a very small cohort of patients and were presented as a result of an ad hoc interim analysis. Noteworthy, careful review of FISH mapping analysis revealed that four out of seven highly FGFR2amp tumour samples were in reality amplified in roughly 20% of cells from tumour section, although no patients with clonal highly FGFR2amp were detected. Only 21% of FGFR2amp Figure 1 . FGFR2 amplification defines a subset of GC patients. The Cancer Genome Atlas Network has proposed a molecular classification of GC into four subtypes: the Ebstein-Barr Virus positive tumours (EBV 8%), characterized by recurrent PI3KCA mutations, high DNA hypermethylation, amplification of JAK2/PDL1 and PDL2/CDKN2A silencing; MicroSatellite Unstable tumours (MSI 22%), characterized by high rates of mutations, including genes that encode oncogenic proteins; genomically stable tumours (GS 20%), enriched by diffuse histology tumours, CDH1/RHOA mutations and some fusions in the CLDN18 family; tumours with chromosomal instability (CIN 50%), enriched by intestinal histology, which show increased amplification of several tyrosine-kinase receptor genes. Among the CIN subgroup we could find the three more frequent non-overlapping molecular alterations described in the overall population of GC: HER2 (17%), FGFR2 (9%) and MET (6%) overexpression. samples translated into high FGFR2 mRNA expression assessed by Nanostring. Unfortunately, although mild signs of effectiveness emerged from early phase 1 and 2 studies testing AZD4547 in FGFR2amp GC patients, none of them met the pre-established efficacy criteria, and both were deemed negative studies. Retrospective careful evaluation of the molecular characteristics of the responders is essential for gaining a better understanding of the oncogenic role of the FGFR2 pathway in GC, and for rationally guiding the identification of predictive biomarkers to FGFRinh.
Predictive biomarkers to FGFR inhibition in gastric cancer
Interestingly, from the data published one may intuit that not all FGFR2amp GC patients respond to the FGFR inhibition. As we gain more scientific evidence of the role of FGFR2 amplification in GC and the therapeutic potential of FGFRinh, many questions remain to be answered: Is there any specific threshold of FGFR2 amplification for benefitting from an FGFRinh? Do we need a specific pattern of FGFR2 amplification distribution? Is it enough with the FGFR2 gene amplification or do we need instead FGFR2 mRNA/protein high expression? Could a determined FGFR2 isoform represent a more sensitive predictive biomarker? Is FGF ligand overexpression mandatory? Could FGFR2 copy number alterations (CNA) detected in circulating free DNA (cfDNA) predict response to FGFRinh?
If we recall the pivotal study that led to the approval of trastuzumab in GC [9] , there were subsets of HER2-amplified (HER2amp) patients that seemed not to benefit from the addition of the targeted agent. A detailed post hoc analysis of the HER2 protein expression in these subgroups of patients revealed that those HER2amp tumours that did not respond had low protein expression (HER2 IHC 0 or IHC 1þ), despite presenting positive FISH for gene amplification. Of note, in this ToGA study patients were considered HER2amp according to a FISH cut off HER2: CEP17 !2. Since then, GC patients are considered HER2amp (IHC 3þ or IHC 2þ/ISHþ by ratio !2) using the defined criteria for detection of HER2 amplification, narrowing the selection criteria to those HER2-positive patients that obtained higher benefit in the ToGA study. Notice that this consensus was extrapolated from revisiting the criteria for HER2amp breast cancer patients [47] . Modifications in GC HER2 interpretation were mandated by clear differences in the physiology (basolateral/lateral staining versus whole round membrane) and heterogeneity (different percentage of positive cells comparing resected primary specimens versus metastatic biopsies) of gastric tumours compared with breast tumours [48] . Noteworthy, there is no consensus yet regarding the optimal criteria for considering a GC FGFR2amp.
To date, most of the initial studies enrolling FGFR2amp patients have established an arbitrary ratio cut off of ! 2 for defining the FGFR gene amplification by FISH. But, do we really know whether we can extrapolate the same threshold used in HER2amp GC for FGFR2amp patients? Bearing this observation in mind, and the molecular characteristics of the initial responders seen in previous mentioned studies with AZD4547, another phase 2 proof-of-concept (POC) study of AZD4547 with FGFR amplified tumours was initiated (NCT01795768). This was an open label non-randomised Simon 2 stage study carried out only in the UK centres, aiming to assess the efficacy of AZD4547 80 mg b.i.d. (2 weeks on/1 week off schedule) monotherapy and the subsequent molecular changes in tumour biopsies. The initial intermittent dosing schedule was subsequently amended to a continuous dosing scheme. Three independent cohorts were assessed, and the FGFR2amp GC/GOJ cohort required centrally verified FGFR2amp by FISH (inclusion criteria ratio >2.2). Initially the primary endpoint was correlation between change in tumour diameter on 8-week CT scan and change in pERK levels comparing pre-treatment and day 10-14 biopsy samples [49] . However, the primary endpoint was changed from PD knockdown of pERK to response rate (RR). Furthermore, PET-CT was carried out at baseline, day 14 and 2-months under treatment, and a thorough biomarker analysis was planned in tumour and plasma, including MIRAX digital FISH imaging, NGS on CNA, FGFR2 gene expression by Nanostring and protein expression by IHC. FGFR CNA was detected in plasma cfDNA by using a droplet digital polymerase chain reaction system.
Twelve out of one hundred thirty-five pre-screened GC patients were positive, with seven of them (5%) presenting high FGFR2 amplification levels (ratio >5). This study met its primary endpoint, with a confirmed RR of 33% in the GC cohort (3 responders out of 9 FGFR2amp GC treated). One of these three GC confirmed responders maintained response for >10 months [50] . Remarkably, all the three responding patients presented high copy number FGFR2 gene amplification, and this was associated with a significant higher expression of both FGFR2 mRNA and protein levels evaluated on the baseline biopsies. Furthermore, using in situ heterogeneity mapping (MIRAX digital FISH) two out of these three responders presented clonal homogeneous FGFR2 amplification (>99% of the tumour cells in the section sample were amplified), whilst non-responding patients were characteristically heterogeneous for FGFR2 amplification distribution. Unfortunately, there was not enough tissue for biomarker assessment from the third responder. Together, all these data suggested that high-level FGFR clonal amplification is key predictive biomarker for FGFRinh, at least in FGFR2amp tumours [51] .
The fact that only 5% of total pre-screened GC patients were highly FGFR2amp (7 out of 135 patients) in this study, indicates that this small patient population may represent a challenge to overcome in future steps of the FGFRinh development. However, the investigators were able to detect elevated FGFR2 copy number in cfDNA of all these three responders, with good correlation with the amplification level in archival tissue. Plasma screening in an additional patient that showed reduction in FDG uptake in day 15 PET CT scan, highlighted also high-level FGFR2amp. In contrast, patients with sub-clonal or low-level FGFR2amp did not present elevated levels of FGFR2 copy number in cfDNA. Together, these results offer the opportunity to consider plasma screening methods as a different but really interesting strategy to identify high FGFR2amp patients, representing a potential feasible assessment for selecting the best candidates.
Finally, the oncogenic potential of certain FGFR2 isoforms has been described [52] . As example, the FGFR2-C3 transforming isoform codifies for an aberrant FGFR, leading to a delayed internalization and subsequent constitutively FRS2-dependent activated signalling [53] . Interestingly, it seems that only GC with high FGFR2amp express this truncated FGFR2-C3 isoform, although not in a uniform level [51] . Published data have recently suggested that FGFR amplified tumours may also require the coexpression of higher FGF ligand levels for responding to FGFRinh, as the co-amplification of FGFR/FGF genes has shown to confer more sensitivity to FGFR inhibition in cell lines [54] . Therefore, both the detection of specific FGFR2 isoforms or FGF ligand over-expression may also represent novel and enriching predictive biomarkers. Figure 2 illustrates several predictive biomarkers proposed for better delineating the FGFRamp GC population that may benefit from an FGFRinh.
One clear limitation seen in these early studies testing AZD4547 was the small n of patients included. Noteworthy, it has to be considered that these studies mainly enrolled a Western population, where the prevalence of FGFR2amp is around 9%. Taking into account the geographical differences in GC, one might question whether the prevalence of highly FGFR2amp patients in Asian countries follows the same prevalence as in Western countries (5% highly FGFR2amp among 9% of total FGFR2amp). The SHINE study may have failed to demonstrate its primary endpoint due to the low pre-established threshold for considering FGFR2amp patients (ratio >2.0), whilst the POC study raised the cut off ratio above 2.2. These observations highlight the importance of contextualizing the observed findings according to each population included and under which criteria. The biomarker analysis and efficacy results of the phase 1 trial in Japanese patients (NCT01213160) will help in clarifying whether this pathway plays a different role in Asian populations that it is worth to explore.
Conclusions
The successful development of new targeted therapies for GC will rely on our capacity of design and implement new personalized strategies. To date, several large randomised phase 3 trials testing targeted agents in first-line GC have resulted negative: the LOGIC study in HER2-positive GC [55] , the EXPAND and REAL-3 studies evaluating the epidermal growth factor receptor blockade [56, 57] , the RILOMET-1 and METGastric studies assessing the role of MET inhibition [58] [59] [60] or the AVAGAST study that considered the anti-angiogenic strategy [61] . Figure 2 . Illustration of potential predictive biomarkers to FGFR/FGF inhibition in FGFR2amp GC. Detection of FGFR2 gene amplification has been the mainstay for pre-screening FGFR2amp patients so far. Nevertheless, not all FGFR2amp patients seem to translate neither into high FGFR2 mRNA levels nor into high FGFR2 protein levels. This correlation may result crucial for predicting response to FGFRinh. On top that, the expression of certain FGFR2-C3 isoforms that codify for constitutively activated FGFR proteins, could represent a potential predictive biomarker of FGFR inhibition. The detailed evaluation of FGFR2amp heterogeneity when analysing a tissue sample by mapping FISH may shed more light regarding the clonal amplification of FGFR2 within the tumour. The assessment of FGFR2 copy number variation (CNV) in circulating tumour DNA (ctDNA) and the identification of FGF ligand over-expression may help in better selecting those patients more likely to benefit from an FGFRinh.
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These disappointing results highlight the unmet medical need that GC continues to represent, and how necessary is to optimize the pre-screening strategies for better selecting small patient populations [62] . Some of these studies had in common that patients were enrolled without a pre-specified molecular biomarker to enrich the study population [56, 57, 61] . Other studies did prescreen patients for a specific molecular alteration, such as HER2 in the LOGIC study or MET in RILOMET-1/METGastric studies [58, 60] , but the molecular aberration selected or the assessment method may not have been the optimal one for predicting response to the corresponding drug-directed therapy. Unless the researchers become aware of the need to identify reliable predictive biomarkers, we risk facing many more discouraging negative trials in the forthcoming years.
Rising evidence positions FGFR2 as an emerging druggable target in FGFR2amp GC patients. However, mild efficacy signs have been seen across early studies testing FGFRinh in this subset population. Figure 3 shows how the accurate evaluation of the data generated in initial trials testing AZD4547 has led to the discovery of potential predictive biomarkers to the FGFR inhibition in GC patients. Careful interpretation of these results seems mandatory for guiding the next steps of FGFRinh development in GC, maybe leading behind the FGFR2 DNA-centred analysis in formalin-fixed paraffin embedded (FFPE) samples. Combined strategies assessing clonal heterogeneity of high FGFR2amp by FISH plus FGFR2 mRNA/protein expression may optimize the identification of the 5% of GC patients more likely to respond. As happened 10 years ago within the ToGA study, the selection of FGFR2amp may mimic the dual strategy for HER2-positive selection, where the current guidelines recommend a combination of IHC threshold/ FISH cut off for defining this positivity. Nevertheless, it has to be considered that not all FGFR2amp may translate into mRNA/protein FGFR2 overexpression, as happens in other tumour subtypes. As example, the analysis of FGFR1amp NSCLC samples demonstrated that not all of them express mRNA FGFR1, and this mRNA expression does not always correlate with the FGFR1 protein expression levels [63] . To add even more complexity, some nonamplified tumours can present high levels of FGFR protein expression which may rescue patients initially considered unresponsive to FGFRinh therapy [64] .
One of the main challenges in FGFR2amp patients will be how to establish a cut off for defining high FGFR mRNA expressers, specially taking into consideration that the FGFR/FGF pathway also plays a key role in normal homeostasis processes of healthy Figure 3 . Identification of predictive biomarkers in early clinical trials testing AZD4547 in GC patients. Accurate retrospective evaluation of the molecular characteristics of GC responders treated with AZD4547 has identified potential biomarkers of response to FGFR inhibition. Here we depict the promising signs of efficacy seen across the phase 1, phase 2 SHINE study and phase 2 proof-of-concept study, and the molecular determinants (highlighted in blue) that were detected among the responding patients. tissues. Will we be able to define a universal threshold for all the tumours or we will need to find a specific pathologic FGFR mRNA level in GC? Scarce data are available regarding mRNA pre-screening methods and their positivity values, although some trials developing FGFRinh have already started to implement them, showing promising improvement in patient selection [34] . On top of that, we will need to consider that GC is characterized by a high incidence of intra-tumoural heterogeneity, which is already known to translate into a poorer correlation between genomic results (assessed by FISH or NGS) and protein expression levels [65] . Quantitative proteomic analysis of FGFR2 may represent a more accurate method for defining a cut off level of protein expression to select best responders, as happens with HER2-positive patients [66, 67] .
Considering these drawbacks, the assessment of FGFR2 CNA in plasmatic samples arises as a very promising pre-screening option, especially for those patients with no archival tissue available or for those in which the FFPE analysis results are inconclusive. Furthermore, the evaluation as biomarkers of response of FGF ligand over-expression or FGFR2-C3 isoform expression certainly warrants further investigation. The relevance of different gene isoforms for predicting response to specific targeted agents has been well described in the literature [68] . Recently, increased p95HER2 levels, a truncated form of the HER2 receptor, have shown to confer resistance to trastuzumab-directed therapy in HER2-positive GC patients [69] .
The future development of FGFRinh in FGFR2amp GC patients will rely on the capacity of identifying suitable predictive biomarkers and to appropriately implement them early in the design of future clinical trials. As it happened before with ALKpositive lung cancer patients, the feasibility of testing GC patients for detecting low prevalence biomarkers emerges as one major challenge. Of note, the PROFILE-1007 study needed to screen a total of 4967 patients during two years for identifying only 347 ALK-positive cases [70] . Crizotinib resulted one of the most successful personalized strategies developed for a molecularly selected population ever. With this, we learnt that ambitious trial designs are possible based on a deeper knowledge of the key molecular target and, if required, with the participation of multiple institutions able to easily enroll patients with an uncommon cancer. GC may be a common cancer, but highly FGFR2amp GC not, and identifying this subset of patients will be essential for enrolling them in a biologically-driven trial with FGFRinh. Accurate and validated companion diagnostics that allow screening of multiple molecular aberrations in a timely manner will play a crucial role in the success of these FGFRinh and other targeted drugs, widening the horizon of treatments for GC patients.
